A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsOriana Ciani, Rod S Taylor, Anthony Muchai Manyara et al.|EClinicalMedicine|2023Cited by 60
COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countriesEng Hooi Tan, Daniel Prieto‐Alhambra, Heba Alghoul et al.|Lara D. Veeken|2021Cited by 53
Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Oriana Ciani, Philippa Davies et al.|BMJ|2024Cited by 45
Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping reviewAnthony Muchai Manyara, Oriana Ciani, Philippa Davies et al.|Journal of Clinical Epidemiology|2023Cited by 30
Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Oriana Ciani, Philippa Davies et al.|BMJ|2024Cited by 28